Q/C Technologies Reports $7.86 Million Net Loss, Shifts Focus to Optical Computing

Q/C Technologies, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $7.86 million for the six months ending June 30, 2026, compared to a loss of $2.92 million during the same period in 2025. The company, which has not generated any product revenue, attributed the increased losses to higher operating expenses, particularly in general and administrative costs, which rose to $2.07 million from $1.74 million year-over-year. Research and development expenses also saw a notable decline, dropping to $746,667 from $2.42 million, primarily due to the suspension of its Phase 2b study of Isomyosamine.

The company’s total assets decreased significantly to $22.87 million as of June 30, 2026, down from $41.17 million at the end of 2025. This decline was largely driven by a reduction in marketable securities, which fell to $10.68 million from $14.80 million. Current liabilities also decreased to $3.57 million from $5.53 million, reflecting a strategic effort to manage cash flow amid ongoing operational losses. The accumulated deficit has now reached $152.19 million, indicating the financial strain the company has faced since its inception.

In terms of strategic developments, Q/C Technologies has shifted its focus from pharmaceutical products to the development of a proprietary silicon photonic computing architecture aimed at artificial intelligence applications. This transition includes the termination of a licensing agreement with LightSolver, which was previously a significant component of its business model. The company is now concentrating on its optical processing unit initiative, which it believes will address the limitations of traditional computing architectures.

Operationally, the company has made changes to its leadership, appointing Todd Fagan as Chief Financial Officer following the termination of Ian Rhodes. Fagan, who has extensive experience in financial reporting and risk management, is expected to guide the company through its current challenges. As of June 30, 2026, Q/C Technologies had a working capital of $8.18 million, which management believes is sufficient to fund operations for the next twelve months, although they acknowledge the need for additional capital to support ongoing development and operational activities.

Looking ahead, Q/C Technologies is focused on advancing its optical computing technologies while evaluating strategic alternatives for its legacy pharmaceutical assets. The company recognizes that its ability to generate revenue will depend on successful product development and market adoption, and it is actively seeking additional funding to support its growth strategy. The management remains optimistic about the potential of its new initiatives but acknowledges the inherent risks and uncertainties associated with the transition.